Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma

6 Sept 2021

Abstract excerpt

Aim: To define the optimal cutoff point for determining methylation status of O6-methylguanine-DNA methyltransferase (MGMT) by pyrosequencing in glioblastoma. Patients & methods: A retrospective study of 109 glioblastoma patients was performed to determine the optimal cutoff point for MGMT methylation status. Results: Receiver operating characteristic (ROC) analysis revealed 21% as the optimal cutoff...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Metastases and Treatment
Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34486380
DOI: 10.2217/cns-2021-0002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastomaPMID 34486380Read ↗

Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patientsSemantic proximity Read ↗

MGMT Pyrosequencing-Based Cut-Off Methylation Level and Clinical Outcome in Patients with Glioblastoma MultiformeSemantic proximity Read ↗

Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter StudySemantic proximity Read ↗

Combining MGMT promoter pyrosequencing and protein expression to optimize prognosis stratification in glioblastomaSemantic proximity Read ↗

MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challengesSemantic proximity Read ↗

Prognostic Role of Methylation Status of theMGMTPromoter Determined Quantitatively by Pyrosequencing in Glioblastoma PatientsSemantic proximity Read ↗

“Hyper-Hypermethylated Status” of the MGMT Gene Promoter Confers Additional Survival Benefits in IDH-Wild-Type Glioblastoma PatientsSemantic proximity Read ↗

Pyrosequencing Analysis of O-6-Methylguanine-DNA Methyltransferase Methylation at Different Cut-Offs of Positivity Associated with Treatment Response and Disease-Specific Survival in Isocitrate Dehydrogenase-Wildtype Grade 4 GlioblastomaSemantic proximity Read ↗

Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastomaSemantic proximity Read ↗

Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patientsSemantic proximity Read ↗

Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questionsSemantic proximity Read ↗

Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.